{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:33:50Z","timestamp":1760783630257},"reference-count":37,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current standard of care (<jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content>) for patients with chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>) and ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>). Although it is effective in a high percentage of patients, this treatment is associated with significant adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s). The next generation of protease inhibitors, simeprevir and faldaprevir, will also be used with <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>. Interferon\u2010free therapy with sofosbuvir appears promising and on the horizon for patients with genotypes 2 and 3, but may still be many years away for patients with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1. The factors which should be considered when deciding whether to treat a patient with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> and mild fibrosis with the current <jats:styled-content style=\"fixed-case\">SOC<\/jats:styled-content> now, or to delay treatment until less toxic and\/or more effective therapy is available is discussed.<\/jats:p>","DOI":"10.1111\/liv.12066","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T11:25:14Z","timestamp":1357212314000},"page":"105-110","source":"Crossref","is-referenced-by-count":18,"title":["Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?"],"prefix":"10.1111","volume":"33","author":[{"given":"Mitchell L.","family":"Shiffman","sequence":"first","affiliation":[{"name":"Liver Institute of Virginia Bon Secours Health System Richmond and Newport News VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Benhamou","sequence":"additional","affiliation":[{"name":"Sercive d'H\u00e9patologie H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24641"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02699.x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02718.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.05.016"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014463"},{"key":"e_1_2_12_11_1","volume":"56","author":"Bronowicki J\u2010P","year":"2012","journal-title":"J Hepatol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.059"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21712"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","unstructured":"PoordadFF LawitzEJ ReddyKR et\u00a0al.Randomized trial comparing ribavirin dose reduction versus erythropoeitin for anemia management in previously untreated patients with chronic hepatitis C receiving Boceprevir plus Peginterferon\/Riba. J Hepatol2012;56(Suppl.): S455.","DOI":"10.1016\/S0168-8278(12)61430-5"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","unstructured":"SulkowskiM RobertsS AfdhalN et\u00a0al.Ribavirin Dose Modification in Treatment\u2010naive and Previously Treated Patients who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies. J Hepatol2012:56(Suppl.):S459\u2013S460.","DOI":"10.1016\/S0168-8278(12)61174-X"},{"key":"e_1_2_12_16_1","first-page":"101A","article-title":"TMC435 in combination with peginterferon and ribavirin in treatment\u2010na\u00efve HCV genotype 1 patients: final analysis of the pillar phase 2b study","volume":"54","author":"Fried M","year":"2011","journal-title":"Hepatology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60062-7"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60068-8"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","unstructured":"ZeuzemS BergT GaneE et\u00a0al.TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon\/ribavirin treatment: Final SVR24 results of the ASPIRE trial. J Hepatol2012;56(Suppl.):S1\u2013S2.","DOI":"10.1016\/S0168-8278(12)60016-6"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","unstructured":"KowdleyKV LawitzE CrespoI et\u00a0al.ATOMIC: 97% RVR for PSI\u20107977+ PEG\/RBV X 12\u00a0week regimen in HCV GT1: An end to response\u2010guided therapy?J Hepatol2012;56(Suppl.):S1.","DOI":"10.1016\/S0168-8278(12)00243-7"},{"key":"e_1_2_12_21_1","unstructured":"GaneEJ StedmanC AndersonJ et\u00a0al.100% Rapid Virologic Response for PSI\u20107977+ Ribavirin in Genotype 1 Null Responders (ELECTRON): Early Viral Decline Similar to that Observed in Genotype 1 and Genotype 2\/3 Treatment\u2010na\u00efve Patients. Presented at CROI 2012."},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","unstructured":"ZeuzemS SorianoV AsselahT et\u00a0al.SVR4 and SVR12 with an interferon\u2010free regimen of BI201335 and BI207127 +\/\u2010 ribavirin in treatment\u2010na\u00efve patients with genotype\u20101 HCV infection: Interim results of SOUND\u2010C2. J Hepatol2012;56(Suppl.):S45.","DOI":"10.1016\/S0168-8278(12)60115-9"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","unstructured":"PoordadF LawitzE KowdleyKV et\u00a0al.12\u2010Week Interferon\u2010Free Regimen of ABT\u2010450\/r+ABT\u2010333+Ribavirin Achieved SVR12 in More Than 90% of Treatment\u2010Na\u00efve HCV Genotype\u20101\u2010Infected Subjects and 47% of Previous Non\u2010Responders. J Hepatol2012;56(Suppl.):S459\u2013S550.","DOI":"10.1016\/S0168-8278(12)61410-X"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","unstructured":"LawitzE PoordadF KowdleyKV et\u00a0al.A 12\u2010Week Interferon\u2010Free Regimen of ABT\u2010450\/r ABT\u2010072 and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment\u2010Na\u00efve HCV IL28B\u2010CC Genotype\u20101\u2010Infected Subject. J Hepatol2012;56(Suppl.):S7.","DOI":"10.1016\/S0168-8278(12)60027-0"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05197.x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61606-7"},{"key":"e_1_2_12_29_1","unstructured":"CheinquerH ShiffmanML ZeuzemS et\u00a0al.The outcome of 24 vs. 48\u00a0weeks of peginterferon alfa\u20102a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N\u2010CORE study. Hepatology2011;56(Suppl.):S156."},{"key":"e_1_2_12_30_1","unstructured":"GaneEJ StedmanCA HylandRH et\u00a0al.Once Daily PSI\u20107977 plus RBV: Pegylated interferon\u2010Alfa not required for Complete Rapid viral response in Treatment\u2010naive Patients with HCV GT2 or GT3. Hepatology2011;54(Suppl.):377A."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.05.010"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.008"},{"key":"e_1_2_12_33_1","unstructured":"HezodeC ShiffmanML CooperC et\u00a0al.Ritonavir\u2010boosted danoprevir plus Peg\u2010IFN\u03b1\u20102a\/ribavirin demonstrates up to 100% SVR24 with 12 or 24\u00a0weeks of total treatment in treatment\u2010naive patients with HCV genotype 4 infection in the DAUPHINE studyJ Hepatology2012;56(Suppl.):118A."},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07642-8"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.007"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707615"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.014"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-103"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:16:22Z","timestamp":1694621782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":37,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/liv.12066"],"URL":"https:\/\/doi.org\/10.1111\/liv.12066","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}